samedan logo
 
 
spacer
home > pmps > autumn 2019 > reliable temperature control
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Reliable Temperature Control





Most biologics require controlled temperature conditions throughout their lifecycle to maintain their efficacy and integrity. By some industry estimates, 25% of such drugs degrade or go to waste due to temperature excursions that result in $16 billion in economic losses and patient safety issues. The industry should aggressively adopt advances in packaging and information technologies such as Internet of Things (IoT) and blockchain to prevent temperature excursions in cold chains.

The Next Big Growth Markets

According to research, the biologics and biosimilar market is expected to reach $399.5 billion by 2025. More than 50% of new drug approvals in 2017 are biologics that require temperaturecontrolled environments, a trend that is anticipated to continue.

Biologics are large molecule drugs that contain a living organism or a component thereof, such as recombinant DNA and deactivated viruses. Biologic drugs are sensitive to their environmental conditions such as temperature, light exposure, humidity, shock, and vibrations and can degrade or spoil when exposed to conditions outside their stability range for a long period of time. Of all the environmental conditions, temperature stands out as the single biggest cause of drug degradation and spoilage.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
About the author


Sujan Thanjavuru is a digital transformation thought leader in the life sciences industry. For over 20 years, Sujan has been partnering with life sciences companies to help reduce time to market of new products and drive enterprise transformation across their value chain. He is also the founder of two health IT start ups, Clinical Data and SafeRxp. Both startups have developed innovative cloudbased cognitive platforms in partnership with Carnegie Mellon University, US. Sujan continues to build innovative new IT platforms that attempt to solve structural industry problems such as counterfeit drugs, broken cold chains, high cost of drug development, and serious adverse drug reactions.


Print this page
Send to a friend
Privacy statement
News and Press Releases

European Commission Approves BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults

 BYANNLI® (6-monthly paliperidone palmitate; PP6M) is the first long-acting injectable schizophrenia treatment to be approved with a twice-yearly dosing regimen[1] . The approval is based on results from the Route 6 Study, which showed that 92.5 percent of patients treated with PP6M were relapse-free at the end of the 12-month double-blind phase1.  
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement